Rasdegafusp alfa
As of the edition of 20 October 2026, Rasdegafusp alfa is a protein: went quiet in 2021; acts on CTAG1A and LY75.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2021
- Kind
- Protein
- Registered trials
- 10, 3 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Hormones; Lungs and airways; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Rasdegafusp alfa.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 7 | 4 | 0 | 3 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Celldex Therapeutics | Lead sponsor of trials | 2009 to now |